CAMBRIDGE, Mass.
--(BUSINESS WIRE)--Dec. 29, 2020--
Moderna, Inc.
(Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today confirmed that the Company is engaged in discussions with the government of
South Korea
to potentially provide 40 million or more doses of the Moderna COVID-19 Vaccine to support South Korea¡¯s aim of providing vaccines to the public as soon as possible. Under the terms of the proposed agreement, distribution would begin in the second quarter of 2021.
¸ð´õ³ª´Â ´ëÇѹα¹ÀÌ ¹é½Å ¼ö±ÞÀ» ÃÖ´ëÇÑ »¡¸® ÇÏ·Á´Â ¸ñÇ¥¸¦ Áö¿øÇϱâ À§ÇØ 40¹Ð ÀÌ»óÀÇ ¹é½Å °ø±Þ¿¡ ´ëÇÑ ³íÀǸ¦ ½ÃÀÛÇß´Ù. ÇÕÀÇµÈ Á¶°Ç¿¡ µû¶ó ºÐ¹è´Â 2021³â 2ºÐ±âºÎÅÍ ½ÃÀÛµÉ °ÍÀÌ´Ù.
À§´Â ¿¹Àü¿¡ ½è´ø ±Û
http://www.etoland.co.kr/bbs/board.php?bo_table=etoboard02&wr_id=471219&sca=%BD%C3%BB%E7%B0%D4%BD%C3%C6%C7&sfl=wr_name%2C1&stx=%B8%B6%B3%E0%C0%C7%B0%A1%B8%B6%BC%DC&spt=-51177
±×¸®°í ÇöÀç µé¾î¿Â ¸ð´õ³ª ¹é½Å ¹°·®
2ºÐ±â¿¡
5¸¸ 5õ ¸í ºÐ
¾îÁ¦, 8ÀÏ¿¡
17¸¸ 7õ ¸í ºÐ
µµÇÕ 23¸¸ 2õ ¸í ºÐ
ÀÌ ¼Óµµ¸é 4ºÐ±âÂë 2õ¸¸ ¸í ºÐ ´Ù µé¾î¿Ã µí.
2022³â 4ºÐ±â¿ä.
Çϱä Àú ¶§µµ ÃÖ´ëÇÑ »¡¸® ÇÏ·Á°í Çß´Ù´Â ¸»¸¸ ÀÖÁö, '»¡¸®, ¸¹ÀÌ'¶ó°í´Â ¾È Çß¾ú³×¿ä.